Welcome to our dedicated page for Puma Biotechnology SEC filings (Ticker: PBYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NERLYNX sales trends, clinical-trial milestones, and royalty obligations are scattered across hundreds of pages of Puma Biotechnology’s SEC reports. Finding exactly where the company discloses HER2-positive breast-cancer data—or when an executive exercises options—can feel impossible.
That’s why Stock Titan pairs every Puma Biotechnology quarterly earnings report 10-Q filing with an AI-powered summary that extracts NERLYNX revenue, R&D spend, and cash-runway details in seconds. Need to decode an 8-K about a Phase III update? Our engine tags the material event and explains what it means for upcoming FDA reviews—think Puma Biotechnology 8-K material events explained. Looking for real-time alerts on Puma Biotechnology Form 4 insider transactions? We post them the moment they hit EDGAR, then highlight trends like cumulative buys before clinical catalysts.
All core submissions are covered: the Puma Biotechnology annual report 10-K simplified to spotlight license milestones and patent cliffs; the proxy statement detailing executive compensation; and each Form 4 showing Puma Biotechnology executive stock transactions Form 4. You can even search “understanding Puma Biotechnology SEC documents with AI” or “Puma Biotechnology SEC filings explained simply” and land here to compare segments, track dilution, or monitor cash burn. Whether you’re verifying a Puma Biotechnology insider trading Form 4 transactions entry or running a Puma Biotechnology earnings report filing analysis, our platform delivers answers—without the biotech jargon.
Form 4 filing overview: Puma Biotechnology (PBYI) Chief Financial Officer Maximo F. Nougues reported two open-market sales of company common stock executed on 07/08/2025 and 07/09/2025.
- Shares sold: 5,587 shares at $3.533 on 07/08/2025 and 3,935 shares at $3.535 on 07/09/2025, totalling 9,522 shares.
- Proceeds: Approximately $33,600 based on the disclosed sale prices.
- Post-sale ownership: 204,229 shares held directly after the second transaction, down from an estimated 213,751 shares before the first sale—an ownership reduction of roughly 4.5%.
- Rule 10b5-1 plan: The filing states the transactions were effected under a pre-established Rule 10b5-1(c) trading plan adopted on 12-14-2020.
The reported activity is routine insider selling rather than a grant or option exercise. Because the sales were pre-planned and represent a modest fraction of the CFO’s remaining stake, the market impact is typically viewed as neutral to slightly negative; insider sales can raise questions about confidence, but the use of a long-standing 10b5-1 plan mitigates concerns of opportunistic timing.
Puma Biotechnology, Inc. (PBYI) Form 4 filing: Senior Vice President of Regulatory Affairs Douglas M. Hunt disclosed two open-market sales executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on 12-14-2020.
- 07/08/2025: Sold 4,374 common shares at $3.533; post-sale holding 168,337 shares.
- 07/09/2025: Sold 3,443 common shares at $3.535; post-sale holding 164,894 shares.
The transactions total 7,817 shares (~4.6% of his reported direct ownership) and were filed by one reporting person. No derivative transactions were reported. Hunt remains an officer of the company.
FAQ
What is the current stock price of Puma Biotechnology (PBYI)?
What is the market cap of Puma Biotechnology (PBYI)?
